Market Newsdesk

MANCHESTER, N.H., May 05, 2021 (GLOBE NEWSWIRE) — Allegro MicroSystems, Inc. (“Allegro” or the “Company”) (Nasdaq:ALGM), a global leader in power and sensing semiconductor solutions for motion control and energy efficient systems, today announced financial results for its fourth fiscal quarter and fiscal year ended March 26, 2021. Record fourth quarter total net sales of $175.1 million for the three-month period exceeded expectations in the fourth quarter and resulted in fiscal year total net sales of $591.2 million. Profitability also exceeded expectations, with improvements in both gross margin and operating income resulting in significant earnings per share growth on both a GAAP and non-GAAP basis sequentially.

Quarter Highlights:

• Total net sales of $175.1 million was up 6.5% sequentially and on a non-GAAP basis, core end markets grew 22.3% from the same period in fiscal 2020.
• Automotive and Industrial net sales for the quarter grew 12.3% and 30.7%, respectively, from the same period in fiscal 2020.
• Gross margin on a GAAP basis was 49.7% and 50.9% on a Non-GAAP basis.
• Operating margin on a GAAP basis was 11.1% and increased to 19.7% on a non-GAAP basis.
• GAAP earnings per diluted share was $0.05, up $0.09 sequentially. Non-GAAP earnings per diluted share was $0.15, up $0.02, growing 15.4% sequentially.

“Our strong performance in the fourth quarter was driven by accelerating revenue in our target markets and increased profitability resulting from continued progress toward our manufacturing transformation,” said Ravi Vig, President and CEO of Allegro MicroSystems. “I am pleased with our design win momentum, which has yielded market share gains and is a testament to our industry-leading technologies and alignment with growing markets like vehicle electrification and data centers. We believe our strengthening fundamentals and resilient manufacturing model give us a solid foundation for long-term out-performance of our end markets.”

Business Summary

Record automotive net sales were up 4% sequentially during the fourth fiscal quarter driven by strong global automotive demand and a favorable vehicle production mix, despite supply chain constraints. Shifts to higher value features on automotive platforms are driving increased demand for Allegro products in ADAS and comfort and convenience systems. Automotive net sales grew 1% for the full year, outpacing an 8% reduction in global car production.

Industrial net sales in the fourth quarter exceeded expectations and were up 23% sequentially and up 21% for the full year, reaching new record highs. Growth was driven by data center, building and factory automation, and green energy applications. All three categories were up double-digits sequentially.

Business Outlook

For the first fiscal quarter ending June 25, 2021, the Company expects total net sales to be in the range of $176 million to $179 million. Non-GAAP gross margin is expected to be about 51.0% and non-GAAP earnings per fully-diluted share for the same period is expected to be in the range of $0.15 to $0.17.

Allegro has not provided a reconciliation of its first fiscal quarter outlook for non-GAAP gross margin and non-GAAP earnings per fully-diluted share because estimates of all of the reconciling items cannot be provided without unreasonable efforts. It is difficult to reasonably provide a forward-looking estimate between such forward-looking non-GAAP measures and the comparable forward-looking GAAP measures. Certain factors that are materially significant to Allegro’s ability to estimate these items are out of its control and/or cannot be reasonably predicted.

Earnings Webcast

A webcast will be held on Wednesday, May 5, 2021 at 8:30 a.m. Eastern time. Ravi Vig, Chief Executive Officer and Paul Walsh, Chief Financial Officer, will discuss Allegro’s financial results.

The webcast will be available on the Investor Relations section of the Company’s website at investors.allegromicro.com. A recording of the webcast will be posted in the same location shortly after the call concludes and will be available for at least 30 days. 

About Allegro MicroSystems

Allegro MicroSystems is a leading global designer, developer, fabless manufacturer and marketer of sensor integrated circuits (“ICs”) and application-specific analog power ICs enabling emerging technologies in the automotive and industrial markets. Allegro’s diverse product portfolio provides efficient and reliable solutions for the electrification of vehicles, automotive ADAS safety features, automation for Industry 4.0 and power saving technologies for data centers and green energy applications.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the expected benefits resulting from our acquisition of Voxtel and our expected financial performance for our first fiscal quarter ending June 25, 2021. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “estimate,” “target,” “mission,” “may,” “will,” “would,” “should,” “could,” “target,” “potential,” “project,” “predict,” “contemplate,” “potential,” or the negative thereof and similar words and expressions.

Forward-looking statements are based on management’s current expectations, beliefs and assumptions and on information currently available to us. Such statements are subject to a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to: downturns or volatility in general economic conditions, including as a result of the COVID-19 pandemic, particularly in the automotive market; our ability to compete effectively with intense competition, expand our market share and increase our profitability; our ability to compensate for decreases in average selling prices of our products; the cyclical nature of the analog semiconductor industry; our ability to manage any sustained yield problems or other delays at our third-party wafer fabrication facilities or in the final assembly and test of our products; our ability to fully realize the benefits of past and potential future initiatives designed to improve our competitiveness, growth and profitability; our ability to accurately predict our quarterly net sales and operating results; our ability to adjust our supply chain volume to account for changing market conditions and customer demand; our dependence on manufacturing operations in the Philippines; changes in government trade policies, including the imposition of tariffs and export restrictions; and our ability to protect our proprietary technology and inventions through patents or trade secrets; and other important factors discussed under the caption “Risk Factors” in our final prospectus on Form 424(b) filed with the U.S. Securities and Exchange Commission (“SEC”) on February 8, 2021, as any such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investors & Media page of our website at investors.allegromicro.com.

All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

ALLEGRO MICROSYSTEMS, INC.
Consolidated Statements of Operations

(in thousands, except share and per share amounts)

	Three-Month Period Ended								Fiscal Year Ended
	(Unaudited)				(Unaudited)				(Unaudited)
	March 26, 2021				March 27, 2020				March 26, 2021				March 27, 2020
Net sales	$	143,017			$	121,997			$	486,546			$	465,532
Net sales to related party	32,091				52,607				104,661				184,557
Total net sales	175,108				174,604				591,207				650,089
Cost of goods sold	88,102				102,846				312,305				388,813
Gross profit	87,006				71,758				278,902				261,276
Operating expenses:
Research and development	28,140				24,487				108,649				102,052
Selling, general and administrative	34,799				28,366				153,476				106,396
Impairment of long-lived assets	7,119				—				7,119				—
Change in fair value of contingent consideration	(2,500		)		—				(2,500		)		—
Total operating expenses	67,558				52,853				266,744				208,448
Operating (loss) income	19,448				18,905				12,158				52,828
Other (expense) income:
Loss on debt extinguishment	—				—				(9,055		)		—
Interest expense, net	(668		)		(50		)		(2,603		)		(110		)
Foreign currency transaction (loss) gain	(1,558		)		(1,409		)		(2,889		)		1,391
Income in earnings of equity investment	6				—				1,413				—
Other, net	(178		)		346				(475		)		(831		)
Income (loss) before income taxes	17,050				17,792				(1,451		)		53,278
Income tax provision (benefit)	8,361				4,463				(19,552		)		16,173
Net  income	8,689				13,329				18,101				37,105
Net income attributable to non-controlling interests	45				33				148				134
Net income attributable to Allegro MicroSystems, Inc.	$	8,644			$	13,296			$	17,953			$	36,971
Net income attributable to Allegro MicroSystems, Inc. per share:
Basic	$	0.05			$	1.33			$	0.22			$	3.70
Diluted	$	0.05			$	1.33			$	0.10			$	3.70
Weighted average shares outstanding:
Basic	189,429,893				10,000,000				83,448,055				10,000,000
Diluted	190,860,556				10,000,000				176,416,645				10,000,000

Supplemental Schedule of Total Net Sales

The following table summarizes net sales by core end market and other applications. Other applications include sales of wafer foundry products and from the distribution of Sanken products unrelated to and no longer part of the Company’s business in fiscal year 2021.

	Three-Month Period Ended								Change								Fiscal Year Ended								Change
	March 26, 2021				March 27, 2020				Amount				%				March 26, 2021				March 27, 2020				Amount				%
	(Dollars in thousands)
Core end markets:
Automotive	$	118,539			$	105,596			$	12,943				12.3	%		$	398,298			$	395,277			$	3,021				0.8	%
Industrial		29,162				22,304			6,858					30.7	%			94,872				78,399			16,473					21.0	%
Other		27,407				15,223			12,184					80.0	%			98,037				68,622			29,415					42.9	%
Total core end markets		175,108				143,123			31,985					22.3	%			591,207				542,298			48,909					9.0	%
Other applications:
Wafer foundry products		—				22,748			(22,748		)			(100.0	)%			—				72,370			(72,370		)			(100.0	)%
Distribution of Sanken products		—				8,733			(8,733		)			(100.0	)%			—				35,421			(35,421		)			(100.0	)%
Total net sales	$	175,108			$	174,604			$	504				0.3	%		$	591,207			$	650,089			$	(58,882	)			(9.1	)%

Supplemental Schedule of Stock-Based Compensation

The Company recorded stock-based compensation expense in the following expense categories of its unaudited consolidated statements of income:

	Three-Month Period Ended								Fiscal Year Ended
(In thousands)	March 26, 2021				March 27, 2020				March 26, 2021				March 27, 2020
Cost of sales	$	314			$	46			$	5,158			$	183
Research and development	536				22				3,573				87
Selling, general and administrative	2,119				316				41,139				1,165
Total stock-based compensation	$	2,969			$	384			$	49,870			$	1,435

Supplemental Schedule of Acquisition Related Intangible Amortization Costs

The Company recorded intangible amortization expense related to its acquisition of Voxtel in the following expense categories of its unaudited consolidated statements of income:

	Three-Month Period Ended								Fiscal Year Ended
(In thousands)	March 26, 2021				March 27, 2020				March 26, 2021				March 27, 2020
Cost of sales	$	273			$	—				651				—
Selling, general and administrative	37				—				117				—
Total intangible amortization	$	310			$	—			$	768			$	—

ALLEGRO MICROSYSTEMS, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)

	(Unaudited)
	March 26, 2021				March 27, 2020
Assets
Current assets:
Cash and cash equivalents	$	197,214			$	214,491
Restricted cash	6,661				5,385
Trade accounts receivable, net of allowances of doubtful accounts of $138 and $288 at March 26, 2021 and March 27, 2020, respectively	69,500				59,457
Trade and other accounts receivable due from related party	23,832				30,851
Accounts receivable – other	1,516				1,796
Inventories	87,498				127,227
Prepaid expenses and other current assets	18,374				9,014
Assets held for sale	25,969				—
Total current assets	430,564				448,221
Property, plant and equipment, net	192,393				332,330
Deferred income tax assets	26,972				7,217
Goodwill	20,106				1,285
Intangible assets, net	36,366				19,958
Equity investment in related party	26,664				—
Other assets, net	14,613				8,810
Total assets	$	747,678			$	817,821
Liabilities, Non-Controlling Interest and Stockholders’ Equity
Current liabilities:
Trade accounts payable	$	35,389			$	20,762
Amounts due to related party	2,353				4,494
Accrued expenses and other current liabilities	78,932				56,855
Current portion of related party debt	—				25,000
Bank lines-of-credit	—				43,000
Total current liabilities	116,674				150,111
Obligations due under Senior Secured Credit Facilities, less current portion	25,000				—
Related party notes payable, less current portion	—				17,700
Other long-term liabilities	19,133				15,878
Total liabilities	160,807				183,689
Commitments and contingencies
Stockholders’ Equity:
Preferred Stock, $0.01 par value; 20,000,000 shares authorized, no shares issued or outstanding at March 26, 2021 and March 27, 2020	—				—
Common stock, $0.01 par value; 1,000,000,000 shares authorized, 189,588,161 shares issued and outstanding at March 26, 2021; no shares authorized, issued or outstanding at March 27, 2020	1,896				—
Class A, $0.01 par value; No shares authorized, issued or outstanding at March 26, 2021; 12,500,000 shares authorized; 10,000,000 shares issued and outstanding at March 27, 2020	—				100
Class L, $0.01 par value; No shares authorized, issued or outstanding at March 26, 2021; 1,000,000 shares authorized; 622,470 shares issued and outstanding at March 27, 2020	—				6
Additional paid-in capital	592,170				458,697
Retained earnings	3,551				194,355
Accumulated other comprehensive loss	(11,865		)		(19,976		)
Equity attributable to Allegro MicroSystems, Inc.	585,752				633,182
Non-controlling interests	1,119				950
Total stockholders’ equity	586,871				634,132
Total liabilities, non-controlling interest and stockholders’ equity	$	747,678			$	817,821

ALLEGRO MICROSYSTEMS, INC.

Consolidated Statements of Cash Flows

(in thousands)

	Fiscal Year Ended
	(Unaudited)
	March 26, 2021				March 27, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	18,101			$	37,105
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	48,307				64,048
Amortization of debt issuance costs	226				—
Deferred income taxes	(18,930		)		(4,909		)
Stock-based compensation	49,870				1,435
Loss on disposal of assets	269				698
Loss on debt extinguishment	9,055				—
Gain on contingent consideration change in fair value	(2,500		)		—
Impairment on assets held for sale	7,119				—
Provisions for inventory and bad debt	5,019				3,891
Changes in operating assets and liabilities:
Trade accounts receivable	(9,303		)		16,441
Accounts receivable – other	(28		)		346
Inventories	7,641				346
Prepaid expenses and other assets	(29,048		)		2,629
Trade accounts payable	15,099				(3,122		)
Due from/to related parties	4,878				(23,946		)
Accrued expenses and other current and long-term liabilities	14,795				(13,543		)
Net cash provided by operating activities	120,570				81,419
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment	(40,673		)		(45,615		)
Acquisition of business, net of cash acquired	(11,555		)		—
Proceeds from sales of property, plant and equipment	318				3,936
Disposal of cash balances of subsidiary	(16,335		)		—
Net cash used in investing activities	(68,245		)		(41,679		)
CASH FLOWS FROM FINANCING ACTIVITIES:
Related party note receivable	51,377				30,000
Proceeds from initial public offering, net of underwriting discounts and other offering costs	321,425				—
Payments for taxes related to net share settlement of equity awards	(27,707		)		—
Dividends paid	(400,000		)		—
Borrowings of senior secured debt, net of deferred financing costs	315,719				43,000
Repayment of senior secured debt	(300,000		)		—
Repayment of unsecured credit facilities	(33,000		)		—
Capital contribution	—				9,500
Net cash (used) provided by financing activities	(72,186		)		82,500
Effect of exchange rate changes on Cash and cash equivalents and Restricted cash	3,860				(5,621		)
Net (decrease) increase in Cash and cash equivalents and Restricted cash	(16,001		)		116,619
Cash and cash equivalents and Restricted cash at beginning of period	219,876				103,257
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD	$	203,875			$	219,876
RECONCILIATION OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH:
Cash and cash equivalents at beginning of period	$	214,491			$	99,743
Restricted cash at beginning of period	5,385				3,514
Cash and cash equivalents and Restricted cash at beginning of period	$	219,876			$	103,257
Cash and cash equivalents at end of period	197,214				214,491
Restricted cash at end of period	6,661				5,385
Cash and cash equivalents and Restricted cash at end of period	$	203,875			$	219,876

Consolidated Statements of Cash Flows (cont.)

(in thousands)

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	$	2,746			$	2,448
Cash paid for income taxes	$	8,908			$	15,873
Non-cash transactions:
Changes in Trade accounts payable related to Property, plant and equipment, net	$	(3,226	)		$	(1,542	)
Assets held for sale transferred from property, plant and equipment, net	$	25,969			$	—
Loans to cover purchase of common stock under employee stock plan	$	171			$	232

Non-GAAP Financial Measures

In addition to the measures presented in our consolidated financial statements, we regularly review other metrics, defined as non-GAAP financial measures by the SEC, to evaluate our business, measure our performance, identify trends, prepare financial forecasts and make strategic decisions. The key metrics we consider are non-GAAP Gross Profit, non-GAAP Gross Margin, non-GAAP Operating Expenses, non-GAAP Operating Income, non-GAAP Operating Margin, non-GAAP Profit before Tax, non-GAAP Provision for Income Tax, non-GAAP Net Income, non-GAAP Net Income per Share, EBITDA, Adjusted EBITDA and Adjusted EBITDA margin (collectively, the “Non-GAAP Financial Measures”). These Non-GAAP Financial Measures provide supplemental information regarding our operating performance on a non-GAAP basis that excludes certain gains, losses and charges of a non-cash nature or that occur relatively infrequently and/or that management considers to be unrelated to our core operations, and in the case of non-GAAP Provision for Income Tax, management believes that this non-GAAP measure of income taxes provides it with the ability to evaluate the non-GAAP Provision for Income Taxes across different reporting periods on a consistent basis, independent of special items and discrete items, which may vary in size and frequency. By presenting these Non-GAAP Financial Measures, we provide a basis for comparison of our business operations between periods by excluding items that we do not believe are indicative of our core operating performance, and we believe that investors’ understanding of our performance is enhanced by our presenting these Non-GAAP Financial Measures, as they provide a reasonable basis for comparing our ongoing results of operations. Management believes that tracking and presenting these Non-GAAP Financial Measures provides management and the investment community with valuable insight into matters such as: our ongoing core operations, our ability to generate cash to service our debt and fund our operations; and the underlying business trends that are affecting our performance. These Non-GAAP Financial Measures are used by both management and our board of directors, together with the comparable GAAP information, in evaluating our current performance and planning our future business activities. In particular, management finds it useful to exclude non-cash charges in order to better correlate our operating activities with our ability to generate cash from operations and to exclude certain cash charges as a means of more accurately predicting our liquidity requirements. We believe that these Non-GAAP Financial Measures, when used in conjunction with our GAAP financial information, also allow investors to better evaluate our financial performance in comparison to other periods and to other companies in our industry.

These Non-GAAP Financial Measures have significant limitations as analytical tools. Some of these limitations are that:

• such measures do not reflect our cash expenditures, or future requirements for capital expenditures or contractual commitments;
• such measures exclude certain costs which are important in analyzing our GAAP results;
• such measures do not reflect changes in, or cash requirements for, our working capital needs;
• such measures do not reflect the interest expense, or the cash requirements necessary to service interest or principal payments on our debt;
• such measures do not reflect our tax expense or the cash requirements to pay our taxes; although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future;
• such measures do not reflect any cash requirements for such replacements; and
• other companies in our industry may calculate such measures differently than we do, thereby further limiting their usefulness as comparative measures.

The Non-GAAP Financial Measures are supplemental measures of our performance that are neither required by, nor presented in accordance with, GAAP. These Non-GAAP Financial Measures should not be considered as substitutes for GAAP financial measures such as gross profit, gross margin, net income or any other performance measures derived in accordance with GAAP. Also, in the future we may incur expenses or charges such as those added back in the calculation of these Non-GAAP Financial Measures. Our presentation of these Non-GAAP Financial Measures should not be construed as an inference that future results will be unaffected by unusual or nonrecurring items.

Our prior disclosure referred to non-GAAP Gross Profit and non-GAAP Gross Margin as Adjusted Gross Profit and Adjusted Gross Margin, respectively. No changes have been made to how we calculate these measures.

Non-GAAP Gross Profit and Non-GAAP Gross Margin

We calculate non-GAAP Gross Profit and non-GAAP Gross Margin excluding the items below from cost of goods sold in applicable periods and we calculate non-GAAP Gross Margin as non-GAAP Gross Profit divided by total net sales.

• PSL and Sanken Distribution Agreement – Represents the elimination of inventory cost amortization and foundry service payment related to one-time costs incurred in connection with the disposition of Polar Semiconductor, LLC (“PSL”) during the fiscal year ended March 26, 2021 (the “PSL Divestiture”).
• Stock-based compensation – Represents non-cash expenses arising from the grant of stock-based awards.
• AMTC Facility consolidation one-time costs – Represents one-time costs incurred in connection with closing of our manufacturing facility in Thailand (the “AMTC Facility”) and transitioning of test and assembly functions to our manufacturing facility in the Philippines (the “AMPI Facility”) announced in fiscal year 2020 consisting of: moving equipment between facilities, contract terminations and other non-recurring charges. The closure and transition of the AMTC Facility was substantially completed as of the end of March 2021. These costs are in addition to, and not duplicative of, the adjustments noted in note (*) below.
• Amortization of acquisition-related intangible assets – Represents non-cash expenses associated with the amortization of intangible assets in connection with the acquisition of Voxtel, Inc., which closed in August 2020.
• COVID-19 related expenses – Represents expenses attributable to the COVID-19 pandemic primarily related to increased purchases of masks, gloves and other protective materials, and overtime premium compensation paid for maintaining 24-hour service at the AMPI Facility.

(*) Non-GAAP Gross Profit and the corresponding calculation of non-GAAP Gross Margin in this release do not include adjustments consisting of:

• Additional AMTC related costs – Represents costs relating to the closing of the AMTC Facility and the transitioning of test and assembly functions to the AMPI Facility in the Philippines announced in fiscal year 2020 consisting of: the net savings expected to result from the movement of work to the AMPI Facility, which facility had duplicative capacity based on the buildouts of the AMPI Facility in fiscal years 2019 and 2018. The elimination of these costs did not reduce our production capacity and therefore did not have direct effects on our ability to generate revenue. The closure and transition of the AMTC Facility was substantially completed as of the end of March 2021.
• Out of period adjustment for depreciation expense of giant magnetoresistance assets (“GMR assets”) – Represents a one-time depreciation expense related to the correction of an immaterial error, related to 2017, for certain manufacturing assets that have reached the end of their useful lives.

Non-GAAP Operating Expenses, non-GAAP Operating Income and non-GAAP Operating Margin

We calculate non-GAAP Operating Expenses and non-GAAP Operating Income excluding the same items excluded above to the extent they are classified as operating expenses, and also excluding the items below in applicable periods. We calculate non-GAAP Operating Margin as non-GAAP Operating Income divided by total net sales.

• Transaction fees – Represents transaction-related legal and consulting fees incurred primarily in connection with (i) the unsuccessful acquisition of a competitor in fiscal year 2019, (ii) the acquisition of Voxtel, Inc. in fiscal year 2020, and (iii) the PSL Divestiture and the transfer of the Sanken products distribution business to PSL in fiscal year 2020, and (iv) one-time transaction-related legal and consulting fees in fiscal 2021.
• Severance – Represents severance costs associated with (i) labor savings initiatives to manage overall compensation expense as a result of the declining sales volume during the applicable period, including a voluntary separation incentive payment plan for employees near retirement and a reduction in force and (ii) the closing of the AMTC Facility and the transitioning of test and assembly functions to the AMPI Facility announced and initiated in fiscal year 2020.
• Impairment of long-lived assets – Represents impairment charge incurred in connection with the planned sale of the AMTC Facility.
• Change in fair value of contingent consideration – Represents the change in fair value of contingent consideration payable in connection with the acquisition of Voxtel, Inc.

(**) Non-GAAP Operating Income in this release does not include adjustments consisting of those set forth in note (*) to the calculation of non-GAAP Gross Profit, and the corresponding calculation of non-GAAP Gross Margin, above or:

• Labor savings – Represents salary and benefit costs related to employees whose positions were eliminated through voluntary separation programs or other reductions in force (not associated with the closure of the AMTC Facility or any other plant or facility) and a restructuring of overhead positions from high-cost to low-cost jurisdictions net of costs for newly hired employees in connection with such restructuring.

EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin


We calculate EBITDA as net income minus interest income (expense), tax provision (benefit), and depreciation and amortization expenses. We calculate Adjusted EBITDA as EBITDA excluding the same items excluded above and also excluding the items below in applicable periods, We calculate Adjusted EBITDA Margin as Adjusted EBITDA divided by total net sales.

• Non-core loss (gain) on sale of equipment – Represents non-core miscellaneous losses and gains on the sale of equipment.
• Miscellaneous legal judgment charge – Represents a one-time charge associated with the final payment of the previously accrued amount payable with respect to a VAT dispute related to the construction of the AMPI Facility.
• Loss on debt extinguishment – Represents one-time costs representing deferred financing costs associated with the $300.0 million of our term loan facility repaid during the year ended March 26, 2021.
• Foreign currency translation loss (gain) – Represents losses and gains resulting from the remeasurement and settlement of intercompany debt and operational transactions, as well as transactions with external customers or vendors denominated in currencies other than the functional currency of the legal entity in which the transaction is recorded.
• Income in earnings of equity investment – Represents our equity method investment in PSL.
• Inventory cost amortization – Represents intercompany inventory transactions incurred from purchases made from PSL in fiscal year 2020. Such costs are one-time incurred expenses impacting our operating results during fiscal year 2021 following the PSL Divestiture. Such costs are not expected to have a continuing impact on our operating results after our second fiscal quarter of fiscal year 2021.
• Foundry service payment – Represents foundry service payments incurred under our Price Support Agreement with PSL in respect to the guaranteed capacity at PSL to support our production forecast and are one-time costs incurred impacting our operating results during fiscal year 2021 following the PSL Divestiture. Such costs are not expected to have a continuing impact on our operating results after fiscal year 2021.

Non-GAAP Profit before Tax and Non-GAAP Net Income

We calculate non-GAAP Profit before Tax as Profit before Tax excluding the same items excluded above and also excluding the item below in applicable periods. We calculate non-GAAP Net Income as Net Income excluding the same items excluded above and also excluding the item below in applicable periods.

• Interest on repaid portion of term loan facility – Represents interest expense associated with the $300.0 million of our term loan facility repaid during the period.

Non-GAAP Provision for Income Tax

In calculating non-GAAP Provision for Income Tax, we have added-back the following to GAAP Provision for Income Taxes:

• Tax effect of adjustments to GAAP results – Represents the estimated income tax effect of the adjustments to non-GAAP Profit Before Tax described above and elimination of discrete tax adjustments.

		Three-Month Period Ended												Fiscal Year Ended
		March 26, 2021				December 25, 2020				March 27, 2020				March 26, 2021				March 27, 2020
		(Dollars in thousands)
Reconciliation of Gross Profit
GAAP Gross Profit		$	87,006			$	74,425			$	71,758			$	278,902			$	261,276
PSL and Sanken distribution agreement		930				1,500				—				8,628				—
Stock-based compensation		314				4,694				46				5,158				183
AMTC facility consolidation one-time costs		625				607				—				2,184				—
Amortization of acquisition-related intangible assets		273				273				—				651				—
COVID-19 related expenses		64				65				—				202				—
Total Non-GAAP Adjustments		2,206				7,139				46				16,823				183
Non-GAAP gross profit*		89,212				81,564				71,804				295,725				261,459
Non-GAAP gross margin		50.9		%		49.6		%		41.1		%		50.0		%		40.2		%

*

Non-GAAP Gross Profit and the corresponding calculation of  non-GAAP Gross Margin do not include adjustments for the following components of our net income: (i) additional AMTC related costs of $—, $1,198, and $2,290 for the three months ended March 26, 2021, December 25, 2020, and March 27, 2020, respectively, and (ii) additional AMTC related costs of $6,553 and $9,361 for the fiscal years ended March 26, 2021 and March 27, 2020, respectively, and out of period adjustment for depreciation expense of GMR assets of $768 and $— for the fiscal years ended March 26, 2021 and March 27, 2020, respectively.

		Three-Month Period Ended												Fiscal Year Ended
		March 26, 2021				December 25, 2020				March 27, 2020				March 26, 2021				March 27, 2020
		(Dollars in thousands)
Reconciliation of Operating Expenses
GAAP Operating Expenses		$	67,558			$	98,649			$	52,853			$	266,744			$	208,448
Research and Development Expenses
GAAP Research and Development Expenses		28,140				30,999				24,487				108,649				102,052
Stock-based compensation		536				2,984				22				3,573				87
AMTC facility consolidation one-time costs		—				1				—				2				—
COVID-19 related expenses		8				32				—				100				—
Transaction fees		—				—				—				18				—
Non-GAAP Research and Development Expenses		27,596				27,982				24,465				104,956				101,965
Selling, General and Administrative Expenses
GAAP Selling, General and Administrative Expenses		34,799				67,650				28,366				153,476				106,396
Stock-based compensation		2,119				38,198				316				41,139				1,165
AMTC facility consolidation one-time costs		1,488				1,620				—				5,626				—
Amortization of acquisition-related intangible assets		37				71				—				117				—
COVID-19 related expenses		250				338				581				4,926				581
Transaction fees		3,727				1,729				2,553				7,426				6,335
Severance		—				(181		)		3,263				156				6,415
Non-GAAP Selling, General and Administrative  Expenses		27,178				25,875				21,653				94,086				91,900
Impairment of long-lived assets		7,119				—				—				7,119				—
Change in fair value of contingent consideration		(2,500		)		—				—				(2,500		)		—
Total Non-GAAP Adjustments		12,784				44,792				6,735				67,702				14,583
Non-GAAP operating expenses *		$	54,774			$	53,857			$	46,118			$	199,042			$	193,865

*

Non-GAAP Operating Expenses do not include adjustments for the following components of our net income: (i) additional AMTC related costs of $—, $19, and $2,621 for the three months ended March 26, 2021, December 25, 2020, and March 27, 2020, respectively, and labor savings costs of $—, $109, and $289 for the three months ended March 26, 2021, December 25, 2020, and March 27, 2020, respectively, and (ii) additional AMTC related  costs of $723 and $11,224 for the fiscal years ended March 26, 2021 and March 27, 2020, respectively, and labor savings costs of $218 and $6,173 for the fiscal years ended March 26, 2021 and March 27, 2020, respectively.

		Three-Month Period Ended												Fiscal Year Ended
		March 26, 2021				December 25, 2020				March 27, 2020				March 26, 2021				March 27, 2020
		(Dollars in thousands)
Reconciliation of Operating Income
GAAP Operating Income (Loss)		$	19,448			$	(24,224	)		$	18,905			$	12,158			$	52,828
PSL and Sanken distribution agreement		930				1,500				—				8,628				—
Stock-based compensation		2,969				45,876				384				49,870				1,435
AMTC facility consolidation one-time costs		2,113				2,228				—				7,812				—
Amortization of acquisition-related intangible assets		310				344				—				768				—
COVID-19 related expenses		322				435				581				5,228				581
Impairment of long-lived assets		7,119				—				—				7,119				—
Change in fair value of contingent consideration		(2,500		)		—				—				(2,500		)		—
Transaction fees		3,727				1,729				2,553				7,444				6,335
Severance		—				(181		)		3,263				156				6,415
Total Non-GAAP Adjustments		$	14,990			$	51,931			$	6,781			$	84,525			$	14,766
Non-GAAP Operating Income *		$	34,438			$	27,707			$	25,686			$	96,683			$	67,594
% of net sales		19.7		%		16.8		%		14.7		%		16.4		%		10.4		%

*

Non-GAAP Operating Income and the corresponding calculation of non-GAAP Operating Margin do not include adjustments for the following components of our net income: (i) additional AMTC related costs of $—, $1,217, and $4,911 for the three months ended March 26, 2021, December 25, 2020, and March 27, 2020, respectively, and labor savings costs of $—, $109, and $289 for the three months ended March 26, 2021, December 25, 2020, and March 27, 2020, respectively, and (ii) additional AMTC related costs of $7,276 and $11,224 for the fiscal years ended March 26, 2021 and March 27, 2020, respectively, labor savings costs of $218 and $6,173 for the fiscal years ended March 26, 2021 and March 27, 2020, respectively, and out of period adjustment for depreciation expense of GMR assets of $768 and $— for the fiscal years ended March 26, 2021 and March 27, 2020, respectively.

		Three-Month Period Ended												Fiscal Year Ended
		March 26, 2021				December 25, 2020				March 27, 2020				March 26, 2021				March 27, 2020
		(Dollars in thousands)
Reconciliation of EBITDA and Adjusted EBITDA
GAAP Net Income (Loss)		$	8,689			$	(5,060	)		$	13,329			$	18,101			$	37,105
Interest expense, net		668				2,598				50				2,603				110
Income tax provision (benefit)		8,361				(30,523		)		4,463				(19,552		)		16,173
Depreciation & amortization		12,082				12,199				16,440				48,307				64,048
EBITDA		$	29,800			$	(20,786	)		$	34,282			$	49,459			$	117,436
Non-core loss (gain) on sale of equipment		156				(7		)		193				442				1,284
Miscellaneous legal judgement charge		—				574				—				574				—
Loss on debt extinguishment		—				9,055				—				9,055				—
Foreign currency translation loss (gain)		1,558				145				1,409				2,889				(1,391		)
Income in earnings of equity method investment		(6		)		(949		)		—				(1,413		)		—
Stock-based compensation		2,969				45,876				384				49,870				1,435
AMTC facility consolidation one-time costs		2,113				2,228				106				7,812				106
COVID-19 related costs		322				435				581				5,228				581
Impairment of long-lived assets		7,119				—				—				7,119				—
Change in fair value of contingent consideration		(2,500		)		—				—				(2,500		)		—
Transaction fees		3,727				1,729				2,553				7,444				6,335
Severance		—				(181		)		3,263				156				6,415
PSL and Sanken distribution agreement		930				1,500				—				8,628				—
Adjusted EBITDA		$	46,188			$	39,619			$	42,771			$	144,763			$	132,201
% of sales		26.4		%		24.1		%		24.5		%		24.5		%		20.3		%

*

Adjusted EBITDA and the corresponding calculation of Adjusted EBITDA Margin do not include adjustments for the following components of our net income: (i) additional AMTC related costs of $—, $1,217, and $4,911 for the three months ended March 26, 2021, December 25, 2020, and March 27, 2020, respectively, and labor savings costs of $—, $109, and $289 for the three months ended March 26, 2021, December 25, 2020, and March 27, 2020, respectively and (ii) AMTC additional costs of $7,276 and $11,224 for the fiscal years ended March 26, 2021 and March 27, 2020, respectively, and labor savings costs of $218 and $6,173 for the fiscal years ended March 26, 2021 and March 27, 2020, respectively.

		Three-Month Period Ended												Fiscal Year Ended
		March 26, 2021				December 25, 2020				March 27, 2020				March 26, 2021				March 27, 2020
		(Dollars in thousands)
Reconciliation of Profit (Loss) before Tax
GAAP Profit (Loss) before Tax		$	17,050			$	(35,583	)		$	17,792			$	(1,451	)		$	53,278
Non-core loss (gain) on sale of equipment		156				(7		)		193				442				1,284
Miscellaneous legal judgment charge		—				574				—				574				—
Loss on debt extinguishment		—				9,055				—				9,055				—
Foreign currency translation loss (gain)		1,558				145				1,409				2,889				(1,391		)
Income in earnings of equity investment		(6		)		(949		)		—				(1,413		)		—
PSL and Sanken distribution agreement		930				1,500				—				8,628				—
Stock-based compensation		2,969				45,876				384				49,870				1,435
Interest on repaid portion of Term Loan Facility		—				2,163				—				2,163				—
AMTC facility consolidation one-time costs		2,113				2,228				106				7,812				106
Amortization of acquisition-related intangible assets		310				344				—				768				—
COVID-19 related expenses		322				435				581				5,228				581
Impairment of long-lived assets		7,119				—				—				7,119				—
Change in fair value of contingent consideration		(2,500		)		—				—				(2,500		)		—
Transaction fees		3,727				1,729				2,553				7,444				6,335
Severance		—				(181		)		3,263				156				6,415
Total Non-GAAP Adjustments		$	16,698			$	62,912			$	8,489			$	98,235			$	14,765
Non-GAAP Profit before tax*		$	33,748			$	27,329			$	26,281			$	96,784			$	68,043

*

Non-GAAP Profit before Tax does not include adjustments for the following components of our net income: (i) additional AMTC related costs of $—, $1,217, and $4,911 for the three months ended March 26, 2021, December 25, 2020, and March 27, 2020, respectively,  and labor savings costs of $—, $109, and $289 for the three months ended March 26, 2021, December 25, 2020, and March 27, 2020, respectively, and (ii) additional AMTC related costs of $7,276 and $11,224 for the fiscal years ended March 26, 2021 and March 27, 2020, respectively, labor savings costs of $218 and $6,173 for the fiscal years ended March 26, 2021 and March 27, 2020, respectively, and out of period adjustment for depreciation expense of GMR assets of $768 and $— for the fiscal years ended March 26, 2021 and March 27, 2020, respectively.

		Three-Month Period Ended												Fiscal Year Ended
		March 26, 2021				December 25, 2020				March 27, 2020				March 26, 2021				March 27, 2020
		(Dollars in thousands)
Reconciliation of Provision for Income Taxes
GAAP Provision (Benefit) for Income Taxes		$	8,361			$	(30,523	)		$	4,463			$	(19,552	)		$	16,173
GAAP effective tax rate		32.0		%		85.8		%		25.1		%		1347.5		%		30.4		%
Tax effect of adjustments to GAAP results		(3,053		)		34,872				1,896				34,486				(2,601		)
Non-GAAP Provision for Income Taxes		$	5,308			$	4,349			$	6,359			$	14,934			$	13,572
Non-GAAP effective tax rate		15.7		%		15.9		%		24.2		%		15.4		%		20.0		%

*

Non-GAAP Provision for Income Taxes does not include tax adjustments for the following components of our net income: additional AMTC related costs, labor savings costs, and out of period adjustment for depreciation expense of GMR assets. The related tax effect of those adjustments to GAAP results were $—, $297 and $652 for the three months ended March 26, 2021, December 25, 2020, and March 27, 2020, respectively, and $1,851 and $3,897 for the fiscal years ended March 26, 2021 and March 27, 2020, respectively.

		Three-Month Period Ended												Fiscal Year Ended
		March 26, 2021				December 25, 2020				March 27, 2020				March 26, 2021				March 27, 2020
		(Dollars in thousands)
Reconciliation of Net Income
GAAP Net Income (Loss)		$	8,689			$	(5,060	)		$	13,329			$	18,101			$	37,105
Non-core loss (gain) on sale of equipment		156				(7		)		193				442				1,284
Miscellaneous legal judgement charge		—				574				—				574				—
Loss on debt extinguishment		—				9,055				—				9,055				—
Foreign currency translation loss		1,558				145				2,800				2,889				—
Income in earnings of equity investment		(6		)		(949		)		(1,391		)		(1,413		)		(1,391		)
PSL and Sanken distribution agreement		930				1,500				—				8,628				—
Stock-based compensation		2,969				45,876				384				49,870				1,435
Interest on repaid portion of Term Loan Facility		—				2,163				—				2,163				—
AMTC facility consolidation one-time costs		2,113				2,228				106				7,812				106
Amortization of acquisition-related intangible assets		310				344				—				768				—
COVID-19 related expenses		322				435				581				5,228				581
Impairment of long-lived assets		7,119				—				—				7,119				—
Change in fair value of contingent consideration		(2,500		)		—				—				(2,500		)		—
Transaction fees		3,727				1,729				2,553				7,444				6,335
Severance		—				(181		)		3,263				156				6,415
Tax effect of adjustments to GAAP results		3,053				(34,872		)		(1,896		)		(34,486		)		2,601
Non-GAAP Net Income		$	28,440			$	22,980			$	19,922			$	81,850			$	54,471
Basic weighted average common shares		189,429,893				124,363,078				10,000,000				83,448,055				10,000,000
Diluted weighted average common shares		190,860,556				181,916,360				10,000,000				176,416,645				10,000,000
Non-GAAP Basic Earnings per Share		$	0.15			$	0.18			$	1.99			$	0.98			$	5.45
Non-GAAP Diluted Earnings per Share		$	0.15			$	0.13			$	1.99			$	0.46			$	5.45

*

Non-GAAP Net Income does not include adjustments for the following components of our net income: (i) additional AMTC related costs of $—, $1,217, and $4,911 for the three months ended March 26, 2021, December 25, 2020, and March 27, 2020, respectively, and labor savings costs of $—, $109, and $289 for the three months ended March 26, 2021, December 25, 2020, and March 27, 2020, respectively, (ii) additional AMTC related costs of $7,276 and $11,224 for the fiscal years ended March 26, 2021 and March 27, 2020, respectively, labor savings costs of $218 and $6,173 for the fiscal years ended March 26, 2021 and March 27, 2020, respectively, and out of period adjustment for depreciation expense of GMR assets of $768 and $— for the fiscal years ended March 26, 2021 and March 27, 2020, respectively, and (iii) the related tax effect of adjustments to GAAP results of $—, $297 and $652 for the three months ended March 26, 2021, December 25, 2020, and March 27, 2020, respectively, and $1,851 and $3,897 for the fiscal years ended March 26, 2021 and March 27, 2020, respectively.

Investor Contact: 
Katherine Blye
Investor Relations
Phone: (603) 626-2306
[email protected]

SAN FRANCISCO, May 05, 2021 (GLOBE NEWSWIRE) — Arkose Labs, provider of online fraud and abuse prevention technology, today released new data on the latest fraud trends, revealing an increase in human-bot hybrid attacks.

The Q2 Arkose Labs Fraud and Abuse Report, released today, indicated an uptick in fraud originating from North America, with the U.S. and Russia vying for the top spot in terms of origination of attacks. Additionally, there was a significant amount of human-driven attacks originating from North America, which could indicate that many who were drawn to fraud to make money during lockdowns have continued on this path.

“Many who dabbled in fraud in 2020 have continued to find the profession profitable and continue on with it instead of returning to legitimate work,” said Vanita Pandey, CMO at Arkose Labs. “There is an increasing amount of people who, while not pursuing fraud as a full-time job, are engaging in activities like fake reviews, disseminating fake information on social media and new user sign-up bonus abuse. This new face of fraud is emerging as a permanent part of the landscape.”

2021 started off busy, with heightened attack volumes carrying over from the end of 2020. However, by the midpoint of Q1 there was a drop off in attacks in most industries – except technology, and media/streaming, which continue to see high fraud levels.

At its peak, the Arkose Labs Network detected 5 million attacks daily during the first half of Q1. The overall attack rate dropped significantly as the quarter went on, from a peak of more than 30% of sessions being identified as malicious, to a much more manageable 17%. This was due to a respite from large-scale, targeted bot attacks. Human-driven fraud however did increase slightly this quarter.

Additional highlights from the report include:

Increase in Human-Driven Fraud – Q1 saw a marked increase in human-based attacks from North America, especially in tech and media, which highlights the continuing presence of fraud farms in carrying out attacks. Humans are required to launch scams on these platforms, which they do by sending phishing messages or malicious links to good users seeking to place malware on their devices or extract sensitive information, which can then be resold at a large profit.

Rise in Malicious Mobile Traffic – Higher levels of fraud originated from mobile devices in Q1, up to 28% of all attacks compared to 16.2% last quarter. This speaks to the importance of protecting the entire digital perimeter.

A Diversification of Attack Type – While 2020 was dominated by account takeovers (ATOs) and login-based attacks, Q1 2021 saw a significant uptick in bots attacks for things like spam, info scraping, in-game abuse, inventory hoarding and API abuse, with a 36% increase in these types of attacks from Q4 2020 to Q1 2021. There was also a 28% increase in payments attacks during that same time period.

Rise of the Cyborgs – The increase in humans launching attacks speaks to the increasing relevance of so-called “cyborg” attacks, with fraudsters deploying a mix of bots and fraud farms to successfully pull off attacks.

Attack of the Smart Devices – In an effort to blend in and appear as legitimate traffic, fraudsters are hijacking the trove of new IPs associated with IoT-connected devices. These IPs are often from a geography not typically known for fraud attacks, such as North America. There were similar levels of attacks originating from Europe and Asia in Q1 2021, with Europe the top attacking geography, with over one third of all attacks. This is largely influenced by the consistent high attack levels seen emanating from Russia.

The Q2 Arkose Labs Fraud and Abuse Report is based on actual user sessions and attack patterns that were analyzed by the Arkose Labs Fraud and Abuse Prevention Platform from January through March 2021. These sessions, spanning account registrations, logins and payments from financial services, ecommerce, travel, social media, gaming and entertainment were analyzed in real-time to provide insights into the evolving fraud and risk landscape. Unsophisticated bot attacks don’t result in a user session and thus have not been included in this report. The report focuses on attacks from fraud outlets that combine state-of-the-art technology with stolen identity credentials and human efforts.

To access the full Q2 2021 Fraud and Abuse Report, please click here.

To learn more about Arkose Labs and its Fraud and Abuse Defense Platform, visit www.arkoselabs.com.

About Arkose Labs

Arkose Labs bankrupts the business model of fraud. Recognized by Gartner as a 2020 Cool Vendor, its innovative approach determines true user intent and remediates attacks in real time. Risk assessments combined with interactive authentication challenges undermine the ROI behind attacks, providing long-term protection while improving good customer throughput. Arkose Labs is based in San Francisco, Calif., with offices in Brisbane, Australia and London, UK. For more information, visit www.arkoselabs.com or on Twitter @ArkoseLabs.

Media Contact:

Paul Wilke

[email protected]

+1-415-881-7995

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/705a6d48-cf69-4e3f-96fd-d5c2f90ce0cb

BOSTON, May 05, 2021 (GLOBE NEWSWIRE) — Block & Leviton LLP announces that the firm is investigating whether ChemoCentryx, Inc. (NASDAQ: CCXI) committed securities fraud. Investors who have lost money should contact the firm to learn more about how they might recover those losses. For more details, please visit https://www.blockleviton.com/cases/ccxi.

What is this all about?

On May 4, 2021, the U.S. Food and Drug Administration released a “Briefing Document” concerning ChemoCentryx’s drug candidate avacopan, which is in development for the treatment of adult patients with anti-neutrophil cytoplasmic autoantibody vasculitis. In this Briefing Document, the FDA wrote that its review team “has identified several areas of concern, raising uncertainties about the interpretability of the[] data” submitted as part of ChemoCentryx’s application, as well as concerns with “the clinical meaningfulness of these results.”

Who is eligible?

On this news, shares closed down 45% after plummeting by as much as 60% in intraday trading on May 4, 2021. Investors who have lost money on their Aterian investment – whether or not they have sold that investment – are potentially eligible and should contact Block & Leviton to learn more.

What is Block & Leviton doing?

Block & Leviton is investigating the potential filing of a securities class action lawsuit to attempt to recover losses on behalf of investors who have lost money.

What should you do next?

If you’ve lost money on your investment, you should contact Block & Leviton to learn more via our case website, by email at [email protected], or by phone at (617) 398-5600.

Why should you contact Block & Leviton?

Many law firms have issued releases about this matter; many of those firms do not actually litigate securities class actions. Block & Leviton is a law firm that actually litigates cases. We are dedicated to obtaining significant recoveries on behalf of defrauded investors through active litigation in the federal courts across the country. Many of the nation’s top institutional investors hire us to represent their interests. You can learn more about us at our website, www.blockleviton.com, or call (617) 398-5600 or email [email protected] with any questions.

This notice may constitute attorney advertising.

CONTACT:
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (617) 398-5600
Email: [email protected]
SOURCE: Block & Leviton LLP
www.blockleviton.com

SAN MATEO, Calif., May 05, 2021 (GLOBE NEWSWIRE) — Ahana, the self-service analytics company for Presto, announced today that CRN^®, a brand of The Channel Company^®, recognized Ahana on its 2021 Big Data 100 list as one of the Coolest Business Analytics Companies. This annual list recognizes the technology vendors that go above and beyond by delivering innovation-driven products and services for solution providers that in turn help enterprise organizations better manage and utilize the massive amounts of business data they generate.

This recognition follows Ahana’s recent distinction by CRN as one of 10 Hot Big Data Companies You Should Watch in 2021. “We are honored to receive these prestigious accolades from one of the industry’s most influential media sources,” said Steven Mih, Cofounder and CEO, Ahana. “This is another validation of tremendous growth in users of the open source Presto project and the innovation of Ahana Cloud for Presto, which brings the power of the most powerful open source distributed SQL query engine to any organization.”

Ahana Cloud for Presto is the first and only cloud-native managed service for Presto on Amazon Web Services (AWS), giving customers complete control and visibility of clusters and their data. Presto is an open source distributed SQL query engine for data analytics. With Ahana Cloud, the power of Presto is now accessible to any data team of any size and skill level.

A team of CRN editors compiled this year’s Big Data 100 list by identifying IT vendors that have consistently made technical innovation a top priority through their offering of products and services for business analytics, systems and platforms, big data management and integration tools, database systems, and data science and machine learning. Over the years, the Big Data 100 list has become an invaluable resource for solution providers that trust CRN to help them find vendors that specialize in data intelligence, insights, and analytics.

“IT vendors featured on CRN’s 2021 Big Data 100 list have demonstrated a proven ability to bring much-needed innovation, insight and industry expertise to the solution providers and customers that need it most,” said Blaine Raddon, CEO of The Channel Company. “I am honored to recognize these companies for their unceasing commitment toward elevating and improving the ways businesses gain value from their data.”

The 2021 Big Data 100 list is available online at https://www.crn.com/news/cloud/the-big-data-100-2021

About Ahana

Ahana, the self-service analytics company for Presto, is the only company with a cloud-native managed service for Presto for Amazon Web Services that simplifies the deployment, management and integration of Presto and enables cloud and data platform teams to provide self-service, SQL analytics for their organization’s analysts and scientists. As the Presto market continues to grow exponentially, Ahana’s mission is to simplify interactive analytics as well as foster growth and evangelize the PrestoDB community. Ahana is a premier member of Linux Foundation’s Presto Foundation and actively contributes to the open source PrestoDB project. Founded in 2020, Ahana is headquartered in San Mateo, CA and operates as an all-remote company. Investors include GV, Lux Capital, and Leslie Ventures. Follow Ahana on LinkedIn, Twitter and PrestoDB Slack.

About The Channel Company
^®

The Channel Company enables breakthrough IT channel performance with our dominant media, engaging events, expert consulting and education, and innovative marketing services and platforms. As the channel catalyst, we connect and empower technology suppliers, solution providers, and end users. Backed by more than 30 years of unequaled channel experience, we draw from our deep knowledge to envision innovative new solutions for ever-evolving challenges in the technology marketplace. www.thechannelcompany.com

Follow The Channel Company®:

Twitter
, LinkedIn, and Facebook

© 2021 The Channel Company, LLC. CRN is a registered trademark of The Channel Company, LLC. All rights reserved.

The Channel Company Contact:

Jennifer Hogan
The Channel Company
[email protected]
  
Ahana Media Contact:
Beth Winkowski
Winkowski Public Relations, LLC
978-649-7189
[email protected]

BANNOCKBURN, Ill., May 05, 2021 (GLOBE NEWSWIRE) — Stericycle, Inc. (Nasdaq: SRCL) today announced that Janet Zelenka, Chief Financial Officer and Chief Information Officer, and Andrew Ellis, Vice President of Investor Relations, will host a fireside chat and investor meetings at Stifel’s 2021 Virtual Cross Sector Insight Conference on Tuesday, June 8, 2021.

FOR FURTHER INFORMATION CONTACT:

Stericycle Investor Relations 1-847-607-2012

About Stericycle, Inc.

Stericycle, Inc., (Nasdaq: SRCL) is a U.S. based business-to-business services company and leading provider of compliance-based solutions that protects people, promotes health and safeguards the environment. Stericycle serves customers in the U.S. and 17 countries worldwide with solutions for regulated waste and compliance services, secure information destruction and patient engagement. For more information about Stericycle, please visit www.stericycle.com.

 

CRANBURY, N.J., May 05, 2021 (GLOBE NEWSWIRE) — PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President & Chief Executive Officer, will present at the Bank of America Healthcare Conference on Thursday, May 13, 2021. The company will also participate in one-on-one investor meetings at the conference.

Details on the presentation can be found below.

Bank of America Healthcare Conference
Date:	Thursday, May 13, 2021
Time:	12:30 PM ET
Webcast:	http://www.veracast.com/webcasts/bofa/hc2021/idMy79HJ.cfm

A replay of the presentation will be available by visiting the “Events & Presentations” section of the PMV Pharmaceuticals website.

About PMV Pharma

PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.  PMV Pharma is headquartered in Cranbury, New Jersey. For more information, please visit www.pmvpharma.com.

Contact

For Investors & Media:

Winston Kung
Chief Financial Officer
[email protected]

BERKELEY HEIGHTS, N.J., May 05, 2021 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report its financial results for the first quarter ended March 31, 2021, after the market close on Thursday, May 13, and will host a corporate update conference call at 4:30pm Eastern Time.

Thursday, May 13 th @ 4:30pm ET
Domestic:	877-423-9813
International:	201-689-8573
Conference ID:	13718937
Webcast:	Webcast Link

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product DefenCath™, a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. DefenCath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product (QIDP), and the NDA received priority review in recognition of its potential to address an unmet medical need. QIDP provides for an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also committed to conducting a clinical study in pediatric patients using a central venous catheter for hemodialysis when the NDA is approved, which will add an additional six months of marketing exclusivity when the study is completed. The Company received a Complete Response Letter from FDA stating that the NDA could not be approved until satisfactory resolution of deficiencies at the contract manufacturing facility, including in-process controls for the filling operation. CorMedix also intends to develop DefenCath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrogels. The Company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers.  Neutrolin^® is CE Marked and marketed in Europe and other territories as a medical device. For more information, visit: www.cormedix.com.

Investor Contact:


Dan Ferry
Managing Director
LifeSci Advisors
[email protected]
(617) 430-7576

Greenville, SC, May 05, 2021 (GLOBE NEWSWIRE) — Gordian, the leading provider of facility and construction cost data, software and expertise, announced today the addition of VFA and Kykloud solutions to its facilities planning portfolio, creating a more comprehensive capital planning suite of solutions for customers.

VFA and Kykloud solutions were previously owned by Accruent, another Fortive operating company. The addition of these solutions enables Gordian to provide data, software and services across the facilities planning workflow, from detailed, technical assessments of asset conditions to strategic capital planning. For Accruent, the transition presents an opportunity to focus its portfolio, expand upon connected workflows and deliver targeted solutions that allow facility owners, operators and occupiers to seamlessly manage their built environments.

“Adding the VFA and Kykloud solutions to our facilities planning portfolio helps Gordian fulfill our commitment of providing robust solutions that address customer needs throughout the entire building lifecycle,” said William Pollak, President of Gordian. “Moving these solutions to Gordian will provide the best experience for customers and the broader Fortive organization.”

The addition of VFA and Kykloud positions Gordian with a best-in-class portfolio of facilities planning solutions that offer a unique combination of technical expertise, streamlined data collection and strategic capital planning and analysis capabilities. This suite of solutions can be tailored to fit customers’ needs and accessed in robust, cloud-based software. From very detailed, in-person engineering-based technical assessments to model-based, remote assessments, Gordian can help customers develop actionable and sustainable capital plans that align with their goals. 

“Like Gordian, Accruent puts our customers’ needs first. This transition will provide those customers with more specialized support for the VFA and Kykloud solutions, as these products have wonderful synergy with Gordian’s broader portfolio,” said Andy Ruse, President of Accruent. “Both current and future VFA and Kykloud customers will benefit from Gordian’s continued investment into its capital planning portfolio and its unique authority in this highly specialized market.”

The addition of these solutions furthers Gordian’s mission to provide solutions across the building lifecycle. From construction planning and building to facility operations, Gordian empowers customers to overcome their business challenges by delivering critical data, innovative technology and extraordinary services. 

 

About Accruent

Accruent (www.accruent.com) is the world’s leading provider of intelligent solutions for the built environment – spanning real estate, physical and digital assets, and the integrated technology systems that connect and control them. Accruent continues to set new expectations for how organizations can use data to transform the way they manage their facilities and assets. With major office locations in Austin, New Orleans, London and Amsterdam, Accruent serves more than 10,000 customers in a wide range of industries in more than 150 countries around the world.

About Gordian

Gordian (www.gordian.com) is the leader in facility and construction cost data, software and services for all phases of the building lifecycle. A pioneer of Job Order Contracting, Gordian’s solutions also include proprietary RSMeans data and Facility Intelligence Solutions. From planning to design, procurement, construction and operations, Gordian’s solutions help clients maximize efficiency, optimize cost savings and increase building quality.

Sarah Huet de Guerville
Gordian
8644518036
[email protected]